Sequana Medical – Executive Interview

Sequana Medical – Executive Interview

Sequana Medical — 3 videos in collection

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent complication of liver disease and heart failure. Its proprietary alfapump and DSR approaches aim to provide significant clinical and quality-of-life benefits in these fluid overload conditions.

In this interview, chief executive officer Ian Crosbie describes the recently reported positive efficacy data from its POSEIDON North American registration study for the alfapump device in recurrent and refractory ascites, and the next steps planned prior to commercialisation in the region. Mr Crosbie also highlights the company’s recent activities and the upcoming development strategy for its DSR 2.0 product, which is being advanced to treat fluid overload in heart failure patients.


You may also be interested in these:

Healthcare

Sequana Medical - executive interview

Healthcare

Sequana Medical – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.